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AIM: SMAD4 immunohistochemistry is considered a valuable prognostic marker in colorectal cancer, but
individual studies have often been small and the results variable. A meta-analysis could potentially clarify these
findings. METHODS: In September 2014, a Pubmed and Google Scholar search was conducted to find
publications that reported the prognostic value of SMAD4 expression. A meta-analysis was performed to clarify
the association between SMAD4 expression and survival outcomes. RESULTS: 137 studies were found, of which
13 were considered eligible. The studies consisted of a total of 3800 patients. Three different endpoints were
taken into account, namely, overall survival (OS), disease-free survival (DFS), and cancer-specific survival (CSS). In
addition, the studies were divided into univariate and multivariate analyses. The pooled hazard ratios were given as
follows: univariate CSS = 1.75 [95% confidence interval (CI): 0.93-3.32; z= 1.69; P= .09]; multivariate CSS = 2.17
(95% CI: 1.56-3.01; z= 4.65; P= .000); univariate DFS = 2.11 (95% CI: 1.36-3.28; z= 3.32; P= .001); multivariate
DFS = 2.15 (95% CI: 1.56-3.01; z= 4.65; P= .000); univariate OS and DFS = 2.30 (95% CI: 1.41-3.73; z= 3.36; P=
.001); univariate OS = 2.28 (95% CI: 1.30-4.00; z= 2.89; P= .004). CONCLUSION: The results of the presented
meta-analyses indicate that SMAD4 expression status using immunohistochemistry is a prognostic marker for
patient survival.
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Colorectal cancer (CRC) is the third most commonly diagnosed
cancer and the second leading cause of cancer death in men and
women combined in the United States [1]. CRC is thought to result
from the accumulation of genetic alterations, which give cells a
survival advantage over surrounding cells. An important genetic
change in CRC is mutation of SMAD4 leading to loss of SMAD4
protein expression. SMAD4 protein expression is lost in approxi-
mately 30% to 40% of the CRCs [2–4] and is associated with
metastasis formation and poor response to chemotherapy [5–8].
SMAD4 is the common mediator of the transforming growth
factor–β and bone morphogenetic protein pathways and is located on
chromosome 18q21. SMAD4 immunohistochemistry correlates very
well with the genetic status as is shown in juvenile polyposis [9].
SMAD4 immunohistochemistry is therefore frequently used to
ascertain the SMAD4 status of a tumor. Although the use of SMAD4
immunohistochemistry as a molecular marker has been studied in
multiple studies, this has mostly been performed in small cohorts and
in different subgroups using different survival endpoints. Moststudies report an association between SMAD4 loss and a poor
prognosis, but this is not consistent. To our knowledge, there has
never been a comprehensive study combining all these results to truly
establish the predictive value of SMAD4 immunohistochemistry for
Table 1. Studies included in meta-analysis
Study Year Country Stage No. of
Patients
Inclusion
Period
AB Dilution Site Age
(year)
Follow-Up Outcome Cytoplasm
Nuclear
Preserved
SMAD4 (%)
Adjusted
Therapy
Alazzouzi [15] 2005 Finland III 86 1993-1997 Santa Cruz
Biotechnology Inc
1:1000 Colon/
rectum
Mean, 70.1 At least 6
years
DFS and
OS
NA 26 No
Alhopuro [5] 2005 Finland III 75 1994-1998 Santa Cruz
Biotechnology Inc
1:1000 Colon/
rectum
Mean, 59 Mean, 8.7
years
DFS and
OS
NA 86.7 Yes
Isaksson-Mettävainio [18] 2006 Sweden I-III 86 1987-1994 Santa Cruz
Biotechnology Inc
1:50 Colon/
rectum
NA NA CSS Nuclear 90.7 No
Bacman [17] 2007 Germany II-III 305 1991-2001 Santa Cruz
Biotechnology Inc
1:50 Colon Median, 64 Median, 91
months
CSS Nuclear 85.6 Yes
Mesker [19] 2009 Netherlands I-II 118 1980-2001 Santa Cruz
Biotechnology Inc
1:400 Colon Mean, 68.2 Up to 25
years
DFS and
OS
Nuclear 76.5 No
Gulubova [20] 2010 Bulgary I-IV 138 1997-2006 Santa Cruz
Biotechnology Inc
1:50 Colon/
rectum
Median, 65 Median, 37.6
months
OS Nuclear 88.4 No
Li [21] 2011 China I-IV 147 2003-2004 Zhongshan
Biotechnology
1:150 Colon NA Up to 5 years DFS and
OS
Nuclear 74.1 No
Baraniskin [22] 2011 Germany IV 190 NA Santa Cruz
Biotechnology Inc
1:100 Colon/
rectum
Mean, 64.4 NA OS Nuclear 65.8 Yes
Ahn [23] 2011 South Korea I-IV 429 1991-2000 Santa Cruz
Biotechnology Inc
1:200 Colon/
rectum
Mean, 57 Median, 56
months
DFS NA 47.3 Yes
Isaksson-Mettävainio [24] 2012 Sweden I-IV 441 1995-2003 Santa Cruz
Biotechnology Inc
1:100 Colon/
rectum
NA NA CSS Nuclear 80.3 Yes
Lampropoulos [25] 2012 Greece I-IV 195 2005-2006 Santa Cruz
Biotechnology Inc
1:100 Colon/
rectum
Mean, 68.6 Median, 56
months
CSS Both 61.5 No
Roth [26] 2012 Switzerland II-III 1381 NA Santa Cruz
Biotechnology Inc
0.2 mg/ml Colon Median, 60 Median, 69
months
OS and
DFS
NA 78.8 Yes
Voorneveld [16] 2013 Netherlands I-IV 209 1983-2004 Santa Cruz
Biotechnology Inc
1:400 Colon Mean, 68.9 Median, 65
months
CSS Nuclear 60 No
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SMAD4 immunohistochemistry expression with survival outcomes.
Methods
Publication Selection
Pubmed and Google Scholar were used to search for potentially
relevant literature. The search entry used was (“colorectal OR large
intestine” OR “large bowel” OR “colon” OR “colonic” OR “rectal”
OR “rectum”) AND (“cancer” OR “carcinoma” OR “tumor” OR
“tumour” OR “neoplasm” OR “cancers”) AND (“SMAD4” OR
“DPC4”) AND (“marker” OR “signature molecule” OR “molecular
marker” OR “markers” OR “biomarkers” OR “biomarker” OR
“marker” OR “prognosis” OR “predictive” OR “survival”). Addi-
tionally, reference lists of the studies found and of systematic reviews
were also checked for potential articles. The search was performed in
September 2014.
First, the abstracts were checked for relevance and full articles were
retrieved when potentially eligible. To be included in the analysis,
studies had to have been performed in resected colorectal carcinomas
and immunohistochemistry for SMAD4 had to have been performed.
One or more of the following endpoints had to be described: overall
survival (OS), disease-free survival (DFS), or cancer-specific survival
(CSS). Both univariate and multivariate analyses were taken into
account, although separately analyzed. All selected studies were
checked according to a 20-point quality control system developed
previously (Table S1) [10–12].
Statistical Analysis
Data were extracted by two independent researchers. When not
reported, the log hazard ratio (HR) and confidence interval (CI) were
extracted using previously published methods [13,14]. The meta-analysis was performed in STATA12 using the metan package. Pooled
HR and 95% CI were calculated for each endpoint (OS, DFS, and
CSS) and presented in a forest plot. An HR N 1 implies a worse
prognosis for SMAD4-negative CRCs. A P value of b .05 was
considered significantly different. Heterogeneity was calculated and
presented as X2 and I2. We chose to perform random effect models
based on the fact that the studies differed in size, country, and most
importantly in the method of scoring and cutoff values. The loge
standard error of the HR and loge HR of each study were plotted in a
funnel plot to assess potential publication bias.Results
Search Results
The search resulted in 137 studies. On the basis of the abstracts, 19
studies were considered eligible, of which 6 were eventually excluded
on the basis of the fact that the HR and CI could not be extracted.
The 13 eligible studies consisted of a total of 3800 patients, ranging
from 86 to 1381 per study. The main characteristics of the studies can
be found in Table 1. We included OS, CSS, and DFS in this study
but analyzed the different endpoints separately. We also made a
distinction between univariate and multivariate analyses. Five studies
only included colon cancer, and the other eight studies included both
colon and rectal cancers. Six studies reported that a portion or all of
the patients received adjuvant chemotherapy after resection. Three
studies did not report the mean or median age and three studies did
not report the mean or median follow-up period. Five studies
reported CSS, five studies reported DFS, and seven studies reported
OS. Eight studies described specifically that only nuclear staining of
SMAD4 was considered positive. One study considered both
cytoplasmic and nuclear staining as positive and four studies did not
Figure 1. Forest plots of the CSS.
20 Meta-Analysis of SMAD4 Immunohistochemistry Voorneveld et al. Translational Oncology Vol. 8, No. 1, 2015describe their scoring methods. All studies used SMAD4 antibodies
produced by Santa Cruz Biotechnology Inc (Dallas, TX) except for Li et
al. who used an antibody from Zhongshan Biotechnology Inc. All
studies except Isaksson-Mettävainio [24] had dichotomized the scoring.
For Isaksson-Mettävainio [24], we have compared the categories
depicted as SMAD4highversus SMAD4loss and we have not considered
the category SMAD4moderate. The mean and median positive SMAD4
score is 70.9% and 76.5%, respectively, with a range of 26% to 90.7%.
Cancer-Specific Survival
Three studies included a univariate CSS with a total of 600 patients
(range 86-305). The pooled HR is 1.75, which is not significantly
different (95% CI: 0.93-3.32; z= 1.69; P= .09; Figure 1). Four
studies included a multivariate CSS with a total of 931 patients (range
86-441). The pooled HR is 2.17, which is significantly different
(95% CI: 1.56-3.01; z= 4.65; P= .000), indicating that SMAD4 loss
is associated with a worse CSS in this pooled multivariate analysis.
Disease-Free Survival
Six studies included a univariate DFS with a total of 2236 patients
(range 75-1381), and three studies included a multivariate DFS witha total of 1646 patients (range 118-1381). The pooled HR for the
univariate DFS is 2.11 (95% CI: 1.36-3.28; z= 3.32; P= .001), and
the pooled HR for the multivariate DFS is 2.15 (95% CI: 1.56-3.01;
z= 4.65; P= .000), which are both significantly different (Figure 2).
The univariate and the multivariate DFS meta-analyses confirm that
SMAD4 loss is associated with a poor DFS.
Overall Survival
Seven studies included a univariate OS with a total of 2135 patients
(range 75-1381), and four studies included a multivariate OS with a
total of 1836 patients (range 118-1381). The pooled HR for the
univariate OS is 2.30 (95% CI: 1.41-3.73; z= 3.36; P= .001), and the
pooled HR for the multivariate OS is 2.28 (95% CI: 1.30-4.00; z=
2.89; P= .004) (Figure 3). Both the univariate and the multivariate OS
meta-analyses showed that SMAD4 loss is associated with a poor OS.
Publication Bias
The funnel plots for the assessment of potential publication bias
show one considerable outlier in the univariate and multivariate OS
and the univariate DFS (Figure 4). Although in the univariate OS this
does not result in a significant Egger test, we chose to exclude the
Figure 2. Forest plots of the DFS.
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Exclusion of the outlier reduces the pooled HR of the univariate OS
to 1.673 (95% CI: 1.42-1.96; z= 6.08; P= .000). The pooled HR of
the multivariate OS is reduced to 1.55 (95% CI: 1.29-1.86; z= 4.68;
P= .000), and the pooled HR of the univariate DFS is 1.6 (95% CI:
1.23-2.08; z= 3.53; P= .000).
Discussion
Molecular profiling of individual tumors potentially allows a
personalized approach to cancer treatment. Estimation of prognosis
plays an important role in decisions about treatment, and this is
currently almost entirely dependent on histopathologic staging.
SMAD4, located on chromosome 18q21, has frequently been reported
to be a useful prognostic marker. Several studies have reported the
prognostic value of SMAD4 expression using immunohistochemistry
[15,16], although this has not been entirely consistent [17]. To ourknowledge, this is the first comprehensive meta-analysis of the
predictive value of SMAD4 expression using immunohistochemistry.
We included three different endpoints, namely OS, CSS, and DFS,
and both univariate and multivariate analyses. All the meta-analyses,
except the univariate CSS, showed a significant difference in HR
implying that loss of SMAD4 expression as measured by immuno-
histochemistry is associated with a poor prognosis. Thirteen studies
have investigated the prognostic value of SMAD4 loss using different
types of endpoints resulting in relative few studies per single
endpoint. The analyses of the univariate OS and DFS included the
largest numbers of studies (seven each), which make these the most
reliable results. To investigate the heterogeneity, I2 was calculated,
which was more than 50% in most of the cases, except for the
univariate and multivariate analyses of the CSS. Conventionally,
when I2 is more than 50% and the distribution is significantly
heterogeneous (Pb .05), the fixed model cannot be used and the
Figure 3. Forest plots of the OS.
22 Meta-Analysis of SMAD4 Immunohistochemistry Voorneveld et al. Translational Oncology Vol. 8, No. 1, 2015random effects model has to be applied, but prior to conducting the
analysis, we had already decided to use the random effects model for
all the meta-analyses because of the variation in the methodology of
the studies included. One aspect that varies between the studies is the
percentage of SMAD4 preservation, which is dependent on the
staining and scoring method used. SMAD4 is the common mediator
of the bone morphogenetic protein/transforming growth factor–β
signaling pathways and complexes with phosphorylated R-SMADs,
which then enter the nucleus to modulate gene transcription. Only
nuclear localization shows active functional SMAD4. Not all studies
used only nuclear staining and four studies did not report what they
considered as positive. Another source of heterogeneity is the
population that was used in each of the studies. Seven studies
included all the stages and the other six included only one or twostages. Six studies included patients that had received chemotherapy,
while in seven studies no adjuvant therapy was applied. These
differences can affect the outcome of the individual studies and can
increase the heterogeneity in the meta-analysis.
Despite the fact that the pooled studies of univariate CSS did not
show a significant difference, we conclude, on the basis of the other
five meta-analyses all showing statistically significant associations, that
immunohistochemical analysis of SMAD4 expression is a useful
prognostic marker in colorectal cancer. Immunohistochemistry is a
relative easy technique to perform and is readily available in most
hospital pathology departments. International recommendations to
standardize SMAD4 scoring methodology are required.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tranon.2014.11.003.
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Figure 4. Funnel plots of all the meta-analyses.
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